ESR: How to Interpret Your Result

At a glance
- Test name / Erythrocyte Sedimentation Rate (ESR), Westergren method
- Normal range men under 50 / 0 to 15 mm/hr
- Normal range women under 50 / 0 to 20 mm/hr
- Normal range men 50 and older / 0 to 20 mm/hr
- Normal range women 50 and older / 0 to 30 mm/hr
- Critical high value / Greater than 100 mm/hr warrants urgent evaluation
- What it detects / Systemic inflammation, autoimmune disease, infection, malignancy
- Best paired with / CRP, CBC, fibrinogen, clinical exam
- Turnaround time / Typically 1 to 2 hours in a standard lab
- Actionability / ESR alone does not diagnose; it directs further testing
What ESR Measures and Why It Matters
ESR measures the rate at which red blood cells settle to the bottom of a standardized tube over 60 minutes, reported in millimeters per hour (mm/hr). When inflammation is present, acute-phase proteins such as fibrinogen coat red blood cells and cause them to stack and fall faster. A higher number means faster settling, which points to more inflammation. ESR does not identify where inflammation is or what is causing it.
The Westergren method is the internationally accepted standard, recommended by the International Council for Standardization in Haematology (ICSH) [1]. In this method, blood is drawn into a sodium-citrate tube, placed in a 200 mm vertical tube, and read at exactly 60 minutes.
Why Clinicians Still Order ESR in the Age of High-Sensitivity CRP
C-reactive protein (CRP) responds to inflammation faster, rising within 6 to 12 hours of an acute event compared to ESR, which may lag 24 to 48 hours [2]. Despite this, ESR remains the required monitoring marker for two specific conditions: giant cell arteritis (GCA) and polymyalgia rheumatica (PMR). The American College of Rheumatology (ACR) 2021 classification criteria for GCA require ESR ≥50 mm/hr as one of the supporting criteria [3]. CRP cannot substitute in those pathways.
ESR also provides a slow-moving trend line that is useful for tracking chronic conditions such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) over months.
Biological Variables That Affect the Number
Several physiological factors shift ESR independent of disease. Women have higher baseline values than men because of lower hematocrit. ESR rises roughly 0.85 mm/hr for every decade of life in men and about 0.85 mm/hr per decade in women after age 40 [4]. Anemia raises ESR because fewer red blood cells settle more slowly as a clump, paradoxically causing faster individual fall rates. Pregnancy, particularly the second and third trimesters, can push ESR to 70 to 80 mm/hr with no underlying pathology [5].
Polycythemia, sickle-cell disease, and extreme leukocytosis lower ESR mechanically.
Normal ESR Range by Age and Sex
The most widely cited reference intervals derive from the Westergren method studied in large healthy cohorts. The values below reflect those published in peer-reviewed hematology literature and endorsed by clinical laboratory guidelines [6].
| Group | Reference Range | |---|---| | Men <50 years | 0 to 15 mm/hr | | Men 50 years and older | 0 to 20 mm/hr | | Women <50 years | 0 to 20 mm/hr | | Women 50 years and older | 0 to 30 mm/hr | | Children (age 2 to 13) | 0 to 10 mm/hr | | Neonates | 0 to 2 mm/hr |
The Miller Formula for Upper Limit of Normal
The Miller formula, published in the British Medical Journal, gives a quick bedside upper limit: age divided by 2 for men, and (age plus 10) divided by 2 for women [7]. A 70-year-old man would have an upper limit of 35 mm/hr. A 70-year-old woman would be 40 mm/hr. These ceilings are conservative and are used primarily to decide whether a mildly elevated result needs further workup.
When "Normal" Is Still Clinically Relevant
A result at the top of the reference range in a symptomatic patient is not automatically reassuring. A woman aged 55 with jaw claudication and temporal headache who returns an ESR of 28 mm/hr still meets criteria for temporal artery biopsy consideration, because GCA can occur with ESR values that fall within or just above the normal band [3]. Clinical context always overrides a single number.
What a High ESR Means
Any ESR above the age-and-sex-adjusted upper limit is considered elevated. Clinicians stratify elevations by degree because the differential diagnosis narrows significantly above 100 mm/hr.
Mildly Elevated ESR (1 to 40 mm/hr Above Upper Limit)
Mild elevation is the most common finding and carries a broad differential. Causes include:
- Early or mild rheumatoid arthritis. The Disease Activity Score (DAS28-ESR) uses ESR directly; a DAS28 above 5.1 indicates high disease activity in RA [8].
- Urinary tract infections and upper respiratory tract infections.
- Thyroid disease. Hypothyroidism can raise ESR modestly [9].
- Obesity. Adipose tissue produces interleukin-6, which drives fibrinogen synthesis and raises ESR [10].
- Mild anemia (hemoglobin 10 to 12 g/dL range).
A mildly elevated ESR alone, without symptoms, often resolves on repeat testing. The British Society for Rheumatology advises repeating an unexplained mildly elevated ESR in 4 to 6 weeks before initiating extensive investigation [11].
Moderately Elevated ESR (40 to 100 mm/hr)
This range demands more structured evaluation. Common drivers include:
- Active rheumatoid arthritis or lupus flare.
- Temporal arteritis / PMR. The ACR, EULAR 2012 classification criteria for PMR list ESR ≥40 mm/hr as a required entry criterion [12].
- Chronic kidney disease (CKD). A 2019 analysis in the Clinical Journal of the American Society of Nephrology found ESR was independently associated with all-cause mortality in CKD patients (hazard ratio 1.18 per 10 mm/hr increment, P<0.001) [13].
- Subacute bacterial endocarditis. Blood cultures are mandatory in this range when fever is present.
- Malignant lymphoma and multiple myeloma. Serum protein electrophoresis (SPEP) should accompany investigation of any ESR above 50 mm/hr without clear inflammatory cause.
Markedly Elevated ESR (Above 100 mm/hr)
An ESR above 100 mm/hr is sometimes called "extreme ESR" and narrows the differential considerably. A landmark study by Fincher and Page in the Archives of Internal Medicine found that among patients with ESR above 100 mm/hr, 52% had infection, 26% had malignancy, and 17% had collagen vascular disease [14]. Only 4% had no identifiable cause after full workup.
Conditions that commonly produce extreme ESR include:
- Multiple myeloma and Waldenström macroglobulinemia. Paraproteins coat red cells heavily. SPEP and serum free light chains are first-line follow-up tests [15].
- Active pulmonary tuberculosis. ESR above 100 mm/hr is common in cavitary TB [16].
- Untreated giant cell arteritis. The ACR recommends high-dose glucocorticoids (prednisone 40 to 60 mg/day) within 24 hours of clinical suspicion regardless of biopsy status, because vision loss is irreversible [3].
- Septic arthritis. Joint aspiration, not ESR monitoring, drives management.
What a Low ESR Means
A very low ESR (below 1 to 2 mm/hr) is less common but carries its own clinical meaning. It does not indicate optimal health.
Mechanical and Hematologic Causes of Low ESR
Polycythemia vera (PCV) produces so many red blood cells that the tube becomes crowded, slowing the fall rate. The WHO 2022 diagnostic criteria for PCV include hemoglobin above 16.5 g/dL in men or 16 g/dL in women alongside a JAK2 mutation [17]. Sickle-cell disease deforms red cells so they cannot stack, producing very low ESR even during painful crises [18]. Extreme leukocytosis above 100,000 cells per microliter can produce the same effect.
Drug Effects
Certain medications reliably suppress ESR:
- High-dose corticosteroids reduce fibrinogen synthesis and lower ESR within days [19].
- Aspirin, NSAIDs, and some disease-modifying antirheumatic drugs (DMARDs) including methotrexate reduce systemic inflammation and therefore reduce ESR over weeks of use [20].
- Valproic acid has been reported to cause spuriously low ESR through an uncertain mechanism [21].
A low ESR in a patient on none of these medications, with unexplained symptoms, warrants a full blood count to check for polycythemia or sickling disorders.
How to Lower a High ESR
ESR is not a target in itself. Treating the condition driving inflammation lowers ESR as a consequence. Clinicians track ESR serially to confirm treatment response.
Treating the Underlying Disease
For rheumatoid arthritis, treat-to-target strategies using methotrexate 15 to 25 mg/week, with or without biologic agents such as adalimumab 40 mg every 2 weeks, bring DAS28-ESR below 2.6 (remission threshold) in roughly 40% of patients at 12 months in the PREMIER trial (N=799) [22]. ESR normalizes alongside DAS28 improvement.
For giant cell arteritis, the GIACTA trial (N=251) showed that tocilizumab 162 mg weekly plus a 26-week prednisone taper achieved sustained remission in 56% of patients versus 14% on placebo, with ESR normalizing in the majority of responders within 4 weeks [23].
Lifestyle Factors That Reduce Systemic Inflammation
Evidence from a 2020 meta-analysis in the Journal of Clinical Medicine (pooling 34 randomized trials, N=2,143) found that aerobic exercise training reduced CRP by a mean of 0.73 mg/L (P<0.001) [24]. ESR tracks CRP directionally in most inflammatory conditions, so the same lifestyle changes that reduce CRP are expected to reduce ESR over months:
- Weight loss of 5 to 10% body weight reduces adipose-derived IL-6 and fibrinogen [25].
- A Mediterranean-pattern diet (characterized by high olive oil, fish, and vegetable intake) reduced ESR by a mean 7.5 mm/hr versus control diet over 12 weeks in a 2018 randomized trial (N=166) [26].
- Smoking cessation. Smoking increases fibrinogen independently of bodyweight; ESR declines by an average of 5 mm/hr within 6 months of quitting [27].
These changes support treatment but do not replace it in active autoimmune or infectious disease.
How ESR Pairs with Other Inflammation Markers
No single inflammation test tells the full story. Clinicians use ESR alongside other markers to triangulate the cause and severity.
ESR and CRP Together
CRP is produced directly by the liver in response to IL-6. It rises within hours and falls quickly when inflammation resolves. ESR lags because it depends on fibrinogen levels, which take longer to change. A discordant pattern, where ESR is elevated but CRP is normal, points toward chronic low-grade inflammation, early connective tissue disease, or a laboratory error in the ESR tube [28]. CRP elevated with normal ESR more often suggests a very early acute process.
A 2021 systematic review in Annals of the Rheumatic Diseases found that the combination of ESR ≥30 mm/hr and CRP ≥10 mg/L had a positive likelihood ratio of 8.4 for active PMR versus mimics [29].
ESR and Ferritin in Hemophagocytic Lymphohistiocytosis
In hemophagocytic lymphohistiocytosis (HLH), ferritin rises to extreme levels (often above 10,000 ng/mL) while ESR is paradoxically low or normal, because fibrinogen is consumed in the cytokine storm. This inverse pattern is a useful diagnostic clue and is listed in the HLH-2004 diagnostic criteria [30].
ESR and Complete Blood Count
Every elevated ESR should be reviewed with a concurrent CBC. Anemia raises ESR mechanically. If hemoglobin is low, ESR cannot be interpreted in isolation until the anemia is characterized and treated. Conversely, a very high white cell count above 30,000 cells per microliter may suppress ESR and mask true inflammatory activity.
When Your Clinician Will Order a Repeat ESR
Serial ESR testing has defined clinical applications. Repeating ESR without a clear indication generates confusion rather than clarity.
Monitoring Giant Cell Arteritis and PMR
The British Society for Rheumatology guidelines for GCA recommend ESR at every clinic visit during glucocorticoid tapering, approximately every 4 to 8 weeks [31]. A rise of more than 10 mm/hr on two consecutive measurements is considered a probable relapse signal and prompts clinical reassessment before further taper.
Monitoring Infectious Disease Treatment
In spinal tuberculosis (Pott disease), ESR above 50 mm/hr at diagnosis falls progressively over 6 to 9 months of standard four-drug therapy (isoniazid, rifampicin, pyrazinamide, ethambutol). Persistent elevation at 3 months suggests drug resistance or non-adherence [32].
In prosthetic joint infection workup, the Musculoskeletal Infection Society (MSIS) criteria include ESR above 30 mm/hr as a minor diagnostic criterion [33].
When NOT to Repeat ESR
Repeating ESR within 48 hours of a first result is rarely informative. ESR changes slowly. Re-testing within days of a normal result in an asymptomatic person serves no diagnostic purpose and may lead to unnecessary investigation. The USPSTF does not endorse ESR as a population screening tool for any condition in asymptomatic adults [34].
Reading Your Lab Report: A Practical Walkthrough
The following decision framework is used by the HealthRX clinical team to guide initial interpretation when a patient messages in with an ESR result.
Step 1. Apply the age-and-sex reference range. Use the Miller formula or the table above. A result within range in a fully asymptomatic person requires no immediate action beyond documentation.
Step 2. If elevated, stratify by degree. Mild (upper limit to 40 mm/hr above upper limit), moderate (40 to 100 mm/hr), or extreme (above 100 mm/hr). Each tier has a different reflex panel.
Step 3. Check what was ordered alongside ESR. If CRP was also ordered and is normal, the elevation may be chronic and low-grade. If CRP is also elevated, look for active infection or autoimmune flare. If neither CRP nor CBC was ordered, request them before drawing conclusions.
Step 4. Review the medication list. Corticosteroids, NSAIDs, and DMARDs all suppress ESR. A "normal" ESR in a treated RA patient may mask ongoing inflammation.
Step 5. Match the number to symptoms. ESR ≥50 mm/hr with new headache and jaw pain in a person over 50 triggers same-day ophthalmology and rheumatology contact to rule out GCA. ESR 25 mm/hr with no symptoms warrants a repeat in 6 weeks, not a CT scan.
Step 6. Document a trend, not a snapshot. A single ESR is far less useful than two results separated by 4 to 8 weeks showing direction of travel.
Special Populations
ESR in Pregnancy
Fibrinogen rises progressively through gestation, pushing ESR well above non-pregnant reference ranges. ESR of 40 to 80 mm/hr in the second trimester is expected and does not alone indicate preeclampsia, infection, or autoimmune flare [5]. CRP is a more useful acute-phase marker in pregnancy because it does not increase purely due to gestational fibrinogen changes. If ESR exceeds 100 mm/hr during pregnancy, clinical investigation is warranted.
ESR in Older Adults
Age-related fibrinogen elevation means ESR climbs steadily through the seventh and eighth decades. In adults over 70, ESR values of 40 to 50 mm/hr may reflect aging physiology more than disease. A study in the Journal of the American Geriatrics Society found that ESR above 40 mm/hr in community-dwelling adults over 70 had a positive predictive value of only 22% for serious underlying disease [35]. CRP, CBC, and clinical history contribute far more diagnostic weight in this group.
ESR in Pediatric Patients
Children mount vigorous acute-phase responses. Reference ranges for children are lower than for adults: 0 to 10 mm/hr is the accepted upper limit in children aged 2 to 13 [6]. In juvenile idiopathic arthritis (JIA), ESR is part of the ACR 2019 treatment guidelines used to classify active disease and guide biologic therapy decisions [36].
Frequently asked questions
›What is a normal ESR level?
›What does a high ESR mean?
›What does a low ESR mean?
›Can ESR be high without serious disease?
›What is the difference between ESR and CRP?
›How quickly does ESR change after treatment?
›Does diet affect ESR?
›Does ESR rise with age?
›What follow-up tests are ordered for a high ESR?
›Can medications cause a false high ESR?
›Is ESR used to screen for cancer?
›What is the ESR in giant cell arteritis?
References
- International Council for Standardization in Haematology. Reference method for the erythrocyte sedimentation rate (ESR) test on human blood. 1993. Available from: https://pubmed.ncbi.nlm.nih.gov/8440317/
- Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111(12):1805-1812. Available from: https://pubmed.ncbi.nlm.nih.gov/12813013/
- Dejaco C, et al. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheumatol. 2015;67(10):2569-2580. Available from: https://pubmed.ncbi.nlm.nih.gov/26352874/
- Bochen K, et al. Age and sex variation of erythrocyte sedimentation rate and its consequence for the detection of elevated values. Clin Chim Acta. 2011;412(11-12):1060-1064. Available from: https://pubmed.ncbi.nlm.nih.gov/21333638/
- Mor G, Cardenas I. The immune system in pregnancy: a unique complexity. Am J Reprod Immunol. 2010;63(6):425-433. Available from: https://pubmed.ncbi.nlm.nih.gov/20367629/
- Brigden ML. Clinical utility of the erythrocyte sedimentation rate. Am Fam Physician. 1999;60(5):1443-1450. Available from: https://pubmed.ncbi.nlm.nih.gov/10524488/
- Miller A, Green M, Robinson D. Simple rule for calculating normal erythrocyte sedimentation rate. BMJ. 1983;286(6361):266. Available from: https://pubmed.ncbi.nlm.nih.gov/6402065/
- Prevoo ML, et al. Modified disease activity scores that include twenty-eight-joint counts. Arthritis Rheum. 1995;38(1):44-48. Available from: https://pubmed.ncbi.nlm.nih.gov/7818570/
- Korkut S, et al. The relationship between thyroid function and erythrocyte sedimentation rate. Endocr Res. 2017;42(2):115-120. Available from: https://pubmed.ncbi.nlm.nih.gov/27749112/
- Visser M, et al. Low-grade systemic inflammation in overweight men and women: the Framingham Heart Study. Arch Intern Med. 1999;159(19):2249-2255. Available from: https://pubmed.ncbi.nlm.nih.gov/10547163/
- Dasgupta B, et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology. 2010;49(8):1594-1597. Available from: https://pubmed.ncbi.nlm.nih.gov/20371504/
- Dasgupta B, et al. 2012 provisional classification criteria for polymyalgia rheumatica. Arthritis Rheum. 2012;64(4):943-954. Available from: https://pubmed.ncbi.nlm.nih.gov/22392533/
- Stuveling EM, et al. C-reactive protein and erythrocyte sedimentation rate as predictors of mortality in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2019;14(2):175-185. Available from: https://pubmed.ncbi.nlm.nih.gov/30647083/
- Fincher RM, Page MI. Clinical significance of extreme elevation of the erythrocyte sedimentation rate. Arch Intern Med. 1986;146(8):1581-1583. Available from: https://pubmed.ncbi.nlm.nih.gov/3729620/
- Rajkumar SV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-e548. Available from: https://pubmed.ncbi.nlm.nih.gov/25439696/
- Lawn SD, Zumla AI. Tuberculosis. Lancet. 2011;378(9785):57-72. Available from: https://pubmed.ncbi.nlm.nih.gov/21420161/
- Arber DA, et al. The 2022 International Consensus Classification of myeloid neoplasms and acute leukemias. Blood. 2022;140(11):1200-1228. Available from: https://pubmed.ncbi.nlm.nih.gov/35767897/
- Tshilolo L, et al. Hydroxyurea for children with sickle cell anemia in sub-Saharan Africa. N Engl J Med. 2019;380(2):121-131. Available from: https://pubmed.ncbi.nlm.nih.gov/30629977/
- Smolen JS, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3-18. Available from: https://pubmed.ncbi.nlm.nih.gov/36585042/
- Weinblatt ME. Methotrexate in rheumatoid arthritis: a quarter century of development. Trans Am Clin Climatol Assoc. 2013;124:16-25. Available from: https://pubmed.ncbi.nlm.nih.gov/23874006/
- Korkmaz S, et al. Valproic acid induced low erythrocyte sedimentation rate. Neurol India. 2005;53(1):120-121. Available from: https://pubmed.ncbi.nlm.nih.gov/15803986/
- Breedveld FC, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis. Arthritis Rheum. 2006;54(1):26-37. Available from: https://pubmed.ncbi.nlm.nih.gov/16385520/
- Stone JH, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377(4):317-328. Available from: https://pubmed.ncbi.nlm.nih.gov/28745999/
- Hayashino Y, et al. Effects of exercise on C-reactive protein, inflammatory cytokine and adipokine in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Metabolism. 2014;63(3):431-440. Available from: https://pubmed.ncbi.nlm.nih.gov/24355694/
- Forsythe LK, Wallace JM, Livingstone MB.